Afatinib is an irreversible, second-generation EGFR TKI [12] which has been shown to have better RR, PFS and overall survival (OS) when used in patients of lung cancer harboring susceptible EGFR mutations, compared with platinum-based chemotherapy [13, 14]. The gene discussed is EGFR; the disease is lung cancer.